First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

被引：0
|
作者：
Wenham, R. M. [1 ,2 ]
Sandhu, S. K. [3 ]
Wilding, G. [4 ]
Sun, L. [5 ]
Toniatti, C. [5 ]
Stroh, M. [5 ]
Carpenter, C. [5 ]
de-Bono, J. [3 ]
Baird, R. [3 ]
Schelman, W. R. [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Div Gynecol Oncol, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Div Expt Therapeut, Tampa, FL 33682 USA
[3] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] Merck & Co Inc, Merck Res Labs, Whitehouse Stn, NJ USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72069-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [21] Final results of the phase I trial of niraparib (MK4827), a poly (ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
    Michie, Caroline Ogilvie
    Sandhu, Shahneen Kaur
    Schelman, William R.
    Molife, L. Rhoda
    Wilding, George
    Omlin, Aurelius Gabriel
    Kansra, Vikram
    Brooks, David G.
    Martell, Robert E.
    Kaye, Stanley B.
    De Bono, Johann Sebastian
    Wenham, Robert Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
    Fong, P. C.
    Boss, D. S.
    Carden, C. P.
    Roelvink, M.
    De Greve, J.
    Gourley, C. M.
    Carmichael, J.
    De Bono, J. S.
    Schellens, J. H.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers
    Nechiporchik, N.
    Lieb, K.
    Marquette, L.
    Polin, L.
    Peters, G. J.
    Chen, A.
    Ethier, S. P.
    LoRusso, P. M.
    Burger, A. M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 64 - 64
  • [25] The novel poly(ADP-ribose) polymerase (PARP)-1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer
    Melisi, Davide
    Ossovskaya, Valeria
    Sherman, Barry M.
    Abbruzzese, James L.
    Chiao, Paul J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3522S
  • [26] Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells
    Wu, Xiaochen
    Li, Qiqi
    Zhang, Fan
    Wang, Lijun
    Wang, Jun
    Fan, Junting
    Di, Guohu
    Guo, Chuanlong
    FOOD AND CHEMICAL TOXICOLOGY, 2021, 147
  • [27] Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
    Valenza, C.
    Mongillo, M.
    Gigli, F.
    Trapani, D.
    Katrini, J.
    Nicolo, E.
    Boldrini, L.
    Bielo, L. Boscolo
    Castellano, G.
    Guidi, L.
    Pellizzari, G.
    Derio, S.
    Lapresa, M.
    Parma, G.
    Derenzini, E.
    Curigliano, G.
    Colombo, N.
    ESMO OPEN, 2024, 9 (09)
  • [28] Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
    Shih, Chi-Ting
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Ibanez, Kristen R.
    Lee, Jung-Min
    CELLS, 2024, 13 (22)
  • [29] Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
    Ni, Jing
    Cheng, Xianzhong
    Zhou, Rui
    Zhao, Qian
    Xu, Xia
    Guo, Wenwen
    Gu, Hongyuan
    Chen, Chen
    Chen, Xiaoxiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    Audeh, M. William
    Carmichael, James
    Penson, Richard T.
    Friedlander, Michael
    Powell, Bethan
    Bell-McGuinn, Katherine M.
    Scott, Clare
    Weitzel, Jeffrey N.
    Oaknin, Ana
    Loman, Niklas
    Lu, Karen
    Schmutzler, Rita K.
    Matulonis, Ursula
    Wickens, Mark
    Tutt, Andrew
    LANCET, 2010, 376 (9737): : 245 - 251
12345